China Grants Priority Review to Amgen's Imdelltra — A Pivotal Catalyst for BeOne Medicines

Event Analysis

China's National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for tarlatamab — branded Imdelltra — on July 16, granting it priority review status. As reported by PharmCube and BioPharma Dive, the drug is developed by BeOne Medicines (formerly BeiGene; Nasdaq: ONC) for extensive-stage small cell lung cancer (ES-SCLC), a notoriously difficult-to-treat indication where patients have very limited post-chemotherapy options. Importantly, this is NDA acceptance into priority review — not final approval — a distinction that matters for near-term trading expectations.

Imdelltra is a first-in-class bispecific T-cell engager targeting DLL3, a protein expressed in approximately 95% of SCLC cases. The FDA granted accelerated approval in May 2024, and Phase 3 data showed a 40% objective response rate and 14.3-month median overall survival — a 5.3-month improvement over chemotherapy, with significantly fewer Grade 3+ adverse events (27% vs. 62%). These are compelling numbers in a disease area where incremental progress has been scarce. China priority review typically compresses timelines from the standard 12+ months down to approximately 3–6 months, materially de-risking the approval pathway.

The commercial structure amplifies the strategic importance: BeOne retains full China commercialization rights, having monetized its ex-China royalties to Royalty Pharma for $885M upfront (plus a $65M option). This deal — confirmed by BioSpace and FiercePharma — left BeOne cash-rich while preserving its most lucrative geographic optionality. Lung cancer is the leading cause of cancer death in China, representing a market that analysts forecast could contribute significantly to Imdelltra's projected peak sales of $2.8 billion by 2035, per the Oncology Pipeline consensus.

What This Means for Traders

For Amgen (AMGN trading at $351.88 as of this writing, down 1.03% over 24 hours), this is a mild positive catalyst rather than a primary driver. Amgen holds global partnership rights and benefits from Imdelltra's expanding footprint — H1 2025 sales reached $215M (predominantly U.S.) — but China revenue will flow primarily to BeOne. Traders holding AMGN should treat the China priority review as a medium-term sentiment boost, with the real inflection point arriving upon final NMPA approval, likely in late 2025 or early 2026. Monitor the DeLLphi-312 frontline trial for the next significant Amgen-specific catalyst.

The broader healthcare and biotech sectors stand to benefit modestly. The S&P 500 Index and NASDAQ 100 Index have limited direct sensitivity to this event, but it reinforces positive sentiment in oncology innovation — a subsector that has faced pressure from pricing reform fears. Peers like AbbVie Inc., Pfizer, Inc., and Merck & Co., Inc. see no direct impact but benefit from the signal that China is maintaining a priority pathway for novel oncology therapies amid ongoing US-China trade tensions. Volatility on AMGN itself is expected to remain contained unless the NMPA issues a final approval or Amgen announces updated Phase 3 data. For a broader view on sector dynamics, see the 2026 Stocks Market Outlook.

Trade Amgen Inc. on CoinUnited.io

Trade AMGN with up to 800xx leverage → | Create Free Account